Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation

Recruiting now

Conditions studied: Multiple Sclerosis, MS

In brief

The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) compared to the same cell types in healthy controls. Additionally, the potential clinical correlation of VISTA expression in the follow-up of MS and CIS patients will be examined. By elucidating the role of VISTA in the pathophysiology of MS, this study will contribute to the literature by exploring its potential as a biomarker and its relevance in the development of novel therapeutic strategies. Specifically, this study will compare VISTA protein secretion in MS patients at the time of their first attack with that of healthy controls. Furthermore, changes in VISTA protein secretion will be assessed in blood samples collected at 6- and 12-month follow-ups, and the correlations of these changes with clinical and laboratory findings will be investigated. Finally, this study aims to determine whether CD4+ and CD8+ T cells, monocytes, and T regulatory (Treg) subgroups in the first attack blood samples of MS patients exhibit similar functional properties in terms of VISTA protein secretion as their counterparts in healthy controls. To achieve this, monocytes and T cell subtypes will be stimulated, and their pro- and anti-inflammatory cytokine responses will be analyzed.

Key facts

Study ID

NCT06957145

Run by

Koç University

People needed

60

Starts

2025-06-30

Expected to finish

2026-12-30

Last updated by the study team

2025-09-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients aged 18 years or older diagnosed with MS or CIS according to the 2017 McDonald criteria.
• No diagnosis of any autoimmune disease or malignancy.
• No new diagnosis of autoimmune disease or malignancy during the 1-year follow-up period.
• No use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling.
• No vaccination within one month prior to blood sampling.
• Not in the menstrual cycle at the time of blood sampling.

You may not qualify if…

• Age below 18 years.
• Presence of a previous or newly diagnosed autoimmune disease or malignancy at the time of blood sampling.
• Use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling.
• Vaccination within one month prior to blood sampling
• Being in the menstrual cycle at the time of blood sampling
• Patients without a definitive MS diagnosis according to the 2017 McDonald criteria will not be included in the study.

Where it is running

• Koc University — Istanbul, Istanbul, Turkey (Türkiye) (enrolling)
• Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic and Neurosurgical Diseases, University of Health Sciences, Istanbul, Turkey — Istanbul, Turkey (Türkiye) (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.